atopaxar

Atopaxar is an oral, small molecule antiplatelet drug that acts as a reversible antagonist of the protease-activated receptor 1 (PAR-1), which is the primary thrombin receptor on human platelets. By blocking PAR-1, atopaxar inhibits thrombin-induced platelet activation and aggregation, thereby interfering with platelet signaling pathways involved in thrombosis. It was developed by Eisai for the treatment of acute coronary syndromes (ACS) and coronary artery disease (CAD), including atherothrombosis and unstable angina pectoris. Clinical trials demonstrated significant inhibition of platelet aggregation with dose-dependent onset and offset; however, development was discontinued after phase II due to safety concerns and lack of clear efficacy advantage over existing therapies[2][4][7][8].

Other names

Atopaxar [USAN:INN]751475-53-3